KEGG   PATHWAY: rfq05235
Entry
rfq05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Rhinolophus ferrumequinum (greater horseshoe bat)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
rfq05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
rfq05235

Organism
Rhinolophus ferrumequinum (greater horseshoe bat) [GN:rfq]
Gene
117023595  HIF1A; hypoxia-inducible factor 1-alpha [KO:K08268]
117021897  EGF; pro-epidermal growth factor isoform X1 [KO:K04357]
117012187  EGFR; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
117013636  GTPase HRas-like [KO:K02833]
117029835  HRAS; LOW QUALITY PROTEIN: GTPase HRas [KO:K02833]
117028978  KRAS; GTPase KRas isoform X1 [KO:K07827]
117014672  NRAS; GTPase NRas [KO:K07828]
117037259  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
117022968  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
117037633  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
117017296  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
117024158  FOS; proto-oncogene c-Fos [KO:K04379]
117027175  JUN; transcription factor AP-1 [KO:K04448]
117032945  EML4; echinoderm microtubule-associated protein-like 4 isoform X1 [KO:K15420]
117027160  phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
117024531  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
117038261  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta isoform X1 [KO:K02649]
117027443  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
117035064  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
117037029  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
117035771  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN isoform X1 [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
117018458  AKT3; RAC-gamma serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
117035083  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
117023560  AKT1; RAC-alpha serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
117026614  MTOR; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
117013759  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
117029822  RPS6KB2; ribosomal protein S6 kinase beta-2 isoform X1 [KO:K04688] [EC:2.7.11.1]
117036177  CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
117021384  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X1 [KO:K07209] [EC:2.7.11.10]
117020791  IKBKG; NF-kappa-B essential modulator isoform X1 [KO:K07210]
117024116  NFKBIA; NF-kappa-B inhibitor alpha [KO:K04734]
117034494  NFKBIB; NF-kappa-B inhibitor beta [KO:K02581]
117020854  NFKBIE; NF-kappa-B inhibitor epsilon [KO:K05872]
117022439  NFKB1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580]
117030742  RELA; transcription factor p65 isoform X1 [KO:K04735]
117029185  IFNG; interferon gamma [KO:K04687]
117020615  IFNGR1; interferon gamma receptor 1 [KO:K05132]
117036042  IFNGR2; interferon gamma receptor 2 [KO:K05133]
117026596  JAK1; tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
117031937  JAK2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
117025725  STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
117013100  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
117037546  TLR2; toll-like receptor 2 [KO:K10159]
117032253  TLR4; toll-like receptor 4 [KO:K10160]
117037242  toll-like receptor 9 isoform X1 [KO:K10161]
117017715  TIRAP; toll/interleukin-1 receptor domain-containing adapter protein isoform X1 [KO:K05403]
117036629  MYD88; myeloid differentiation primary response protein MyD88 isoform X1 [KO:K04729]
117030261  TRAF6; TNF receptor-associated factor 6 [KO:K03175] [EC:2.3.2.27]
117011750  NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X1 [KO:K04446]
117016044  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
117035268  NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
117037587  TICAM1; TIR domain-containing adapter molecule 1 [KO:K05842]
117024760  TIR domain-containing adapter molecule 2-like [KO:K05409]
117032458  CD274; programmed cell death 1 ligand 1 isoform X1 [KO:K06745]
117025963  PDCD1; programmed cell death protein 1 isoform X1 [KO:K06744]
117028744  PTPN6; LOW QUALITY PROTEIN: tyrosine-protein phosphatase non-receptor type 6 [KO:K05697] [EC:3.1.3.48]
117017450  PTPN11; tyrosine-protein phosphatase non-receptor type 11 isoform X1 [KO:K07293] [EC:3.1.3.48]
117026506  tyrosine-protein phosphatase non-receptor type 11-like [KO:K07293] [EC:3.1.3.48]
117014341  BATF3; basic leucine zipper transcriptional factor ATF-like 3 isoform X1 [KO:K09034]
117029859  BATF2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034]
117022902  BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
117034484  CSNK2A2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
117015854  CSNK2A1; casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
117019755  CSNK2B; casein kinase II subunit beta [KO:K03115]
117028935  CD4; T-cell surface glycoprotein CD4 [KO:K06454]
117027840  LCK; tyrosine-protein kinase Lck [KO:K05856] [EC:2.7.10.2]
117030447  CD3E; T-cell surface glycoprotein CD3 epsilon chain [KO:K06451]
117029892  CD3G; T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
117017992  uncharacterized protein LOC117017992 [KO:K10785]
117014428  CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
117029810  CD3D; T-cell surface glycoprotein CD3 delta chain [KO:K06450]
117019310  tyrosine-protein kinase ZAP-70 isoform X1 [KO:K07360] [EC:2.7.10.2]
117013390  MAP3K3; mitogen-activated protein kinase kinase kinase 3 isoform X1 [KO:K04421] [EC:2.7.11.25]
117018399  dual specificity mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
117013305  MAP2K3; dual specificity mitogen-activated protein kinase kinase 3 isoform X1 [KO:K04432] [EC:2.7.12.2]
117013904  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 isoform X1 [KO:K04433] [EC:2.7.12.2]
117020595  MAPK13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
117029085  MAPK11; mitogen-activated protein kinase 11 isoform X1 [KO:K04441] [EC:2.7.11.24]
117029232  MAPK12; mitogen-activated protein kinase 12 isoform X1 [KO:K04441] [EC:2.7.11.24]
117016461  MAPK14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
117019393  LAT; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
117015909  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 isoform X1 [KO:K01116] [EC:3.1.4.11]
117035970  PPP3CB; LOW QUALITY PROTEIN: serine/threonine-protein phosphatase 2B catalytic subunit beta isoform [KO:K04348] [EC:3.1.3.16]
117022051  PPP3CA; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
117037738  PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
117032505  PPP3R2; calcineurin subunit B type 2 [KO:K06268]
117033213  PPP3R1; calcineurin subunit B type 1 isoform X1 [KO:K06268]
117023358  RASGRP1; RAS guanyl-releasing protein 1 [KO:K04350]
117026063  CD28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
117019234  PRKCQ; protein kinase C theta type isoform X1 [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
rfq04010  MAPK signaling pathway
rfq04020  Calcium signaling pathway
rfq04066  HIF-1 signaling pathway
rfq04151  PI3K-Akt signaling pathway
rfq04514  Cell adhesion molecules
rfq04620  Toll-like receptor signaling pathway
rfq04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system